Nebulized hypertonic saline 3% for 1 versus 3 days in hospitalized bronchiolitis: a blinded non-inferiority randomized controlled trial

Gaëlle Beal, Catherine Barbier, Sophie Thoret, Amandine Rubio, Mathilde Bonnet, Roseline Mazet, Anne Ego, Isabelle Pin, Gaëlle Beal, Catherine Barbier, Sophie Thoret, Amandine Rubio, Mathilde Bonnet, Roseline Mazet, Anne Ego, Isabelle Pin

Abstract

Background: The use and optimal duration of treatment with nebulized hypertonic saline (HS) in infants hospitalized for acute bronchiolitis is unclear. The objective was to compare the efficacy of 1 versus 3 days of nebulized 3% HS at 72 h of treatment. We conducted a blinded non-inferiority randomized controlled trial including infants aged less than 12 months old, hospitalized for a moderate bronchiolitis.

Methods: Nebulisations of 3% HS for 1 day were followed by either the continuation of 3% HS (HS3d group) or switched to 0.9% normal isotonic saline (HS1d group) for 2 days Randomization was performed according to a predefined list with a 1:1 ratio, obtained with a random generator number with blocks.. Main outcome was mean Wang clinical severity score (CSS) after 72 h of treatment.

Results: One hundred sixteen infants (HS1d n = 59 and HS3d n = 57), were included over two epidemic seasons from 2014 to 2016, but recruitement did not reach the planned sample size. The difference for the Wang CSS score in the HS3d vs HS1d group was 0.71 [IC 90% 0.1; 1.3], above the precluded value of 0.4 set in the protocol defining the non-inferiority of shorter treatment duration. Clinical remission was more rapidly obtained in the HS3d than in HS1d (2.3 ± 1.6 vs 2.9 ± 1.4 days, p = 0.04), with a non-significant tendency for less need of nutritional support and supplemental oxygen in HS3d group. Clinical worsening and treatment intolerance were similar in the 2 groups.

Conclusions: Despite being underpowered, results seem not to be in favour of reducing the duration of nebulised HS treatment from 3 to 1 day in acute moderate bronchiolitis.

Trial registration: Clinical trials NCT02538458, October 2014.

Keywords: Bronchiolitis; Children; Hypertonic saline.

Conflict of interest statement

The authors declare that they have no competing interest.

Figures

Fig. 1
Fig. 1
CONSORT flow diagram
Fig. 2
Fig. 2
Wang CSS evolution by group

References

    1. Che D, Caillere N, Brosset P, Vallejo C, Josseran L. Burden of infant bronchiolitis: data from a hospital network. Epidemiol Infect. 2010;138:573–575. doi: 10.1017/S0950268809990951.
    1. Hartling L, Fernandes RM, Bialy L, Milne A, Johnson D, Plint A, et al. Steroids and bronchodilators for acute bronchiolitis in the first two years of life: systematic review and meta-analysis. BMJ. 2011;342:d1714. doi: 10.1136/bmj.d1714.
    1. Mandelberg A, Amirav I. Hypertonic saline or high volume normal saline for viral bronchiolitis: mechanisms and rationale. Pediatr Pulmonol. 2010;45(1):36–40. doi: 10.1002/ppul.21185.
    1. Wang EE, Milner RA, Navas L, Maj H. Observer agreement for respiratory signs and oximetry in infants hospitalized with lower respiratory infections. Am Rev Respir Dis. 1992;145(1):106–109. doi: 10.1164/ajrccm/145.1.106.
    1. Zhang L, Mendoza-Sassi RA, Wainwright C, Klassen TP. Nebulised hypertonic saline solution for acute bronchiolitis in infants. Cochrane Database Syst Rev. 2013;(7):CD006458.
    1. Maguire C, Cantrill H, Hind D, Bradburn M, Everard ML. Hypertonic saline (HS) for acute bronchiolitis: systematic review and meta-analysis. BMC Pulm Med. 2015;15:148. doi: 10.1186/s12890-015-0140-x.
    1. Zhang L, Mendoza-Sassi RA, Wainwright C, Klassen TP. Nebulised hypertonic saline solution for acute bronchiolitis in infants. Cochrane Database Syst Rev. 2017;12:CD006458. doi: 10.1002/14651858.
    1. Brooks CG, Harrison WN, Ralston SL. Association between hypertonic saline and hospital length of stay in acute viral bronchiolitis: a reanalysis of 2 meta-analyses. JAMA Pediatr. 2016;170(6):577–584. doi: 10.1001/jamapediatrics.2016.0079.
    1. Ralston SL, Lieberthal AS, Meissner HC, Alverson BK, Baley JE, Gadomski AM, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014;134(5):e1474–e1502. doi: 10.1542/peds.2014-2742.
    1. Angoulvant F, Bellêttre X, Milcent K, Teglas JP, Claudet I, Le Guen CG, Efficacy of 3% Hypertonic Saline in Acute Viral Bronchiolitis (GUERANDE) Study Group et al. Effect of nebulized hypertonic saline treatment in emergency departments on the hospitalization rate for acute bronchiolitis: a randomized clinical trial. JAMA Pediatr. 2017;5:e171333. doi: 10.1001/jamapediatrics.2017.1333.
    1. Zhang L, Gunther CB, Franco OS, Klassen TP. Impact of hypertonic saline on hospitalization rate in infants with acute bronchiolitis: a meta-analysis. Pediatr Pulmonol. 2018;53(8):1089–1095. doi: 10.1002/ppul.24066.
    1. Chen Yen-Ju, Lee Wen-Li, Wang Chuang-Ming, Chou Hsin-Hsu. Nebulized Hypertonic Saline Treatment Reduces Both Rate and Duration of Hospitalization for Acute Bronchiolitis in Infants: An Updated Meta-analysis. Pediatrics & Neonatology. 2014;55(6):431–438. doi: 10.1016/j.pedneo.2013.09.013.
    1. Heikkilä P, Korppi M. Nebulised hypertonic saline inhalations do not shorten hospital stays in infants with bronchiolitis. Acta Paediatr. 2016;105(9):1036–1038. doi: 10.1111/apa.13448.
    1. Baron J, El-Chaar G. Hypertonic saline for the treatment of bronchiolitis in infants and young children: a critical review of the literature. J Pediatr Pharmacol Ther. 2016;21(1):7–26. doi: 10.5863/1551-6776-21.1.7.
    1. Teunissen J, Hochs AH, Vaessen-Verberne A, Boehmer AL, Smeets CC, Brackel H, et al. The effect of 3 and 6% hypertonic saline in viral bronchiolitis: a randomised controlled trial. Eur Respir J. 2014;44(4):913–921. doi: 10.1183/09031936.00159613.
    1. Wu S, Baker C, Lang ME, Schrager SM, Liley FF, Papa C, et al. Nebulized hypertonic saline for bronchiolitis: a randomized clinical trial. JAMA Pediatr. 2014;168(7):657–663. doi: 10.1001/jamapediatrics.2014.301.
    1. Kuzik BA, Al-Qadhi SA, Kent S, Flavin MP, Hopman W, Gander S. Nebulized hypertonic saline in the treatment of viral bronchiolitis in infants. J Pediatr. 2007;151(3):266–270. doi: 10.1016/j.jpeds.2007.04.010.
    1. Luo Z, Fu Z, Liu E, Xu X, Fu X, Peng D, et al. Nebulized hypertonic saline treatment in hospitalized children with moderate to severe viral bronchiolitis. Clin Microbiol Infect. 2011;17(12):1829–1833. doi: 10.1111/j.1469-0691.2010.03304.x.
    1. Luo Z, Liu E, Luo J, Li S, Zeng F, Yang X, et al. Nebulized hypertonic saline/salbutamol solution treatment in hospitalized children with mild to moderate bronchiolitis. Pediatr Int. 2010;52(2):199–202. doi: 10.1111/j.1442-200X.2009.02941.x.
    1. Morikawa Y, Miura M, Furuhata MY, Morino S, Omori T, Otsuka M, et al. Nebulized hypertonic saline in infants hospitalized with moderately severe bronchiolitis due to RSV infection: a multicenter randomized controlled trial. Pediatr Pulmonol. 2018;53(3):358–365. doi: 10.1002/ppul.23945.
    1. Everard ML, Hind D, Ugonna K, Freeman J, Bradburn M, Cooper CL, et al. SABRE: a multicentre randomised control trial of nebulised hypertonic saline in infants hospitalised with acute bronchiolitis. Thorax. 2014;69(12):1105–1112. doi: 10.1136/thoraxjnl-2014-205953.
    1. Auger Katherine A., Parker Michelle W., Huang Bin. New Method, Same Answer: We Do Not Know if Hypertonic Saline Helps Bronchiolitis. Pediatrics. 2018;142(3):e20181868. doi: 10.1542/peds.2018-1868.
    1. Harrison Wade, Angoulvant Francois, House Samantha, Gajdos Vincent, Ralston Shawn L. Hypertonic Saline in Bronchiolitis and Type I Error: A Trial Sequential Analysis. Pediatrics. 2018;142(3):e20181144. doi: 10.1542/peds.2018-1144.
    1. Badgett RG, Vindhyal M, Stirnaman JT, Gibson CM, Halaby R. A living systematic review of nebulized hypertonic saline for acute bronchiolitis in infants. JAMA Pediatr. 2015;169(8):788–789. doi: 10.1001/jamapediatrics.2015.0681.
    1. Zhang L, Mendoza-Sassi RA, Klassen TP, Wainwright C. Nebulized hypertonic saline for acute bronchiolitis: a systematic review. Pediatrics. 2015;136(4):687–701. doi: 10.1542/peds.2015-1914.
    1. Barben J, Kuehni CE. Hypertonic saline for acute viral bronchiolitis: take the evidence with a grain of salt. Eur Respir J. 2014;44(4):827–830. doi: 10.1183/09031936.00129914.
    1. Ralston S, Hill V, Martinez M. Nebulised hypertonic saline without adjunctive bronchodilators for children with bronchiolitis. Pediatrics. 2010;126:e520–e525. doi: 10.1542/peds.2009-3105.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj